Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

MASH is typically linked to obesity and often to type 2 diabetes. In a trial in 2020 involving 320 people, Newsome and his colleagues found that a daily semaglutide injection led to reduced liver ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.